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Abstract 
Background: The influence of adjuvant chemotherapy on the survival of gastric adenocarcinoma patients in a stage‑
specific manner is controversial.
Methods: To further explore this topic, we retrospectively analyzed the impact of adjuvant chemotherapy on the 
clinical outcomes of 77 stage II and 117 stage III patients diagnosed between January 2008 and December 2012.
Results: All 194 patients underwent radical operation plus D2 dissection, and were followed a median time of 23.3 
(range 0.4–80.2) months. Median patient age was 67.7 (range 33.9–97.5) years. Adjuvant chemotherapy prolonged the 
relapse‑free survival [22.9 (95 % confidence interval 9.4–36.4) vs. 14.2 (95 % CI 8.6–19.8) months, P = 0.009] and overall 
survival [32.3 (95 % CI 22.6–42.0) vs. 13.4 (95 % CI 9.5–17.2) months, P < 0.001] for patients with stage III, but not stage 
II, disease. Higher overall survival from adjuvant chemotherapy in stage II patients with node involvement did not 
reach the level of statistical significance (P = 0.102). To reduce the selection bias, 142 patients aged <75 years were 
included in a subgroup analysis in which the benefit of adjuvant chemotherapy on relapse‑free survival and overall 
survival were demonstrated for patients with stage III disease.
Conclusions: Adjuvant chemotherapy prolongs relapse‑free and overall survival for patients with stage III gastric 
cancer in a real‑world situation. Tailoring therapy based on different characteristics for patients with stage II gastric 
cancer may produce better outcomes.
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Background
Gastric cancer is the fourth most common cancer and 
second most common cause of cancer death globally, 
with a higher prevalence in East Asia (Hartgrink et  al. 
2009). The GLOBOCAN database from 1993 to 2001 
showed that 933,293 patients were diagnosed with and 
699,803 patients died of gastric cancer yearly (Kamangar 
et al. 2006). For patients diagnosed with non-metastatic 
gastric cancer, surgical resection has been the mainstay 
treatment modality.
People receiving operation for gastric cancer without 
adjuvant chemotherapy are at risk for disease recurrence. 
Results of the 15-year follow-up of the Dutch D1D2 trial 
suggested a 49  % recurrence rate after D1 lymph node 
dissection, and a 40  % recurrence rate after D2 lymph 
node dissection (Songun et al. 2010). In the study, more 
than 40 % of patients had stage I gastric cancer in either 
the D1 or D2 group. Patients with stage II gastric cancer 
accounted only for 24 and 23 %, and patients with stage 
III for 22 and 22  % in the D1 and D2 groups, respec-
tively [staging according to American Joint Committee 
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on Cancer (AJCC), 5th edition] (Fleming et  al. 1997). 
In Eastern countries, D2 dissection is widely used post-
operatively to reduce the recurrence rate. Data from 
a recent randomized trial enrolling only patients with 
II-IIIB gastric cancer revealed a 36 % recurrence rate in 
5 years for patients without adjuvant chemotherapy after 
D2 dissection (Noh et al. 2014).
The value of adjuvant chemotherapy has been widely 
reviewed (Earle and Maroun 1999; Hejna et al. 2006; Fuji-
tani 2013; Oh and Bang 2013). Before 2000, there was 
no large-scaled randomized phase III trial to evaluate 
the benefit of adjuvant chemotherapy on the survival of 
patients with gastric cancer after operation. Information 
on adjuvant chemotherapy in gastric cancer is largely 
derived from meta-analyses. Although some meta-anal-
yses suggested a positive effect of adjuvant chemotherapy 
on survival of patients with gastric cancer (Hejna et  al. 
2006; Mari et  al. 2000; Paoletti et  al. 2010; Diaz-Nieto 
et  al. 2013; Sun et  al. 2009), no impact on survival had 
also been reported (Hermans et al. 1993). Even in meta-
analyses with positive findings, a general agreement for 
adjuvant chemotherapy was not reached. Some studies 
suggested that adjuvant chemotherapy only be recom-
mended for patients with positive lymph node (Earle and 
Maroun 1999), or not recommended because the benefit 
was small (Janunger et al. 2002). Fortunately, in the last 
decade, randomized, placebo-controlled, phase III clini-
cal trials have proven the survival advantage conferred by 
adjuvant chemotherapy after D2 lymph node dissection 
(Noh et  al. 2014; Sakuramoto et  al. 2007; Sasako et  al. 
2011; Bang et al. 2012).
Although the value of adjuvant chemotherapy for gas-
tric cancer is reaching general agreement by the results 
of phase III trials, there are few studies addressing the 
individual stage-specific benefit of adjuvant chemother-
apy. The populations of patients and the inclusion criteria 
used in different studies were not the same (Sakuramoto 
et al. 2007; Bang et al. 2012; Nakajima et al. 2007). Addi-
tionally, the individual values of adjuvant chemotherapy 
for individual stage II or stage III were not the primary 
endpoints and thus were less addressed in the trials from 
the beginning. Although there were subgroup analyses, 
the benefits of adjuvant chemotherapy for stage II or 
stage III were not universal between trials. In the sub-
group analysis of an S-1 adjuvant study, patients with 
stage II and IIIA disease had a 5-year relapse-free sur-
vival and a 5-year overall survival benefit from adjuvant 
S-1 (Sasako et  al. 2011). However, only patients with 
stage II gastric cancer benefited from adjuvant chemo-
therapy with capecitabine plus oxaliplatin (XELOX) for a 
5-year overall survival rate (Noh et al. 2014).
In this study, we reviewed the medical history of 
patients with stage II or stage III gastric cancer who 
received D2 lymph node dissection at our hospital (China 
Medical University Hospital) between January 2009 and 
December 2012. The relapse-free survival and overall 
survival of patients with adjuvant chemotherapy were 
compared to patients without adjuvant chemotherapy. 
The effect of adjuvant chemotherapy was further exam-
ined in a stage-specific manner.
Patients and methods
Patients
We performed a retrospective review of patients who 
were pathologically diagnosed as having stage II or 
stage III gastroesophageal junction (GEJ) or gastric 
adenocarcinoma after radical surgery and D2 lymph 
node dissection at China Medical University Hospital 
between January 2008 and December 2012. All infor-
mation was obtained under a protocol approved by the 
China Medical University Hospital internal review board 
(CMUH105-REC1-047) in accordance with the ethical 
standards of the responsible committee on human exper-
imentation and with the Helsinki Declaration of 1975. 
All pathologies were reviewed and reclassified according 
to the definition by AJCC 7th edition (Edge et al. 2010). 
Total gastrectomy was performed for patients with can-
cer of GEJ or upper gastric body, while subtotal gastrec-
tomy was done for patients with cancer from lower body, 
antrum and pylorus. Patients with performance status of 
Eastern Cooperative Oncology Group (ECOG) 4 were 
excluded. In total, there were 77 patients with stage II 
gastric cancer and 117 patients with stage III gastric can-
cer. These patients were followed through October 2014.
Adjuvant chemotherapy
According to the guidelines of our hospital, all patients 
with stage II or stage III gastric cancer were advised to 
receive adjuvant chemotherapy or concurrent chemo-
radiation. However, the final decision was made by the 
patient. The regimen of adjuvant chemotherapy for 
patients with stage II gastric cancer was a fluorouracil 
derivative (5-fluorouracil intravenously, UFT, capecit-
abine or S1 orally). For patients with stage III gastric 
cancer, the regimen of adjuvant chemotherapy was a 
combination of a platinum (cisplatin, carboplatin or 
oxaliplatin) and a fluorouracil derivative (5-fluorouracil 
intravenously or S1 orally). The adjuvant chemotherapy 
of intravenous medications (5-fluorouracil, cisplatin, car-
boplatin or oxaliplatin) will be given for 6 months, while 
oral fluorouracil derivative (UFT, capecitabine or S1) will 
be given for 12 months.
Post‑operative evaluation
All patients were followed and monitored accord-
ing to the guidelines of our hospital. Patients receive 
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esophagogastroduodenoscopic examination within 
6–12  months after operation. In addition, patients 
received a computed tomography (CT) examination 
every 3–6 months for 2 years, followed by a CT examina-
tion every 6 months for 3 more years.
Prognostic variables
To evaluate the effect of adjuvant chemotherapy on 
patient survival, clinical prognostic variables were col-
lected for analysis, including gender, age, history of 
smoking, history of alcohol consumption, history of pre-
vious gastric operation for non-cancerous cause, perfor-
mance status, preoperative carcinoembryonic antigen 
(CEA) value, preoperative CA19-9 value, and features 
of the pathology. The latter category included tumor 
size (T1, T2, T3 and T4), lymph node involvement (N0, 
N1, N2, N3), differentiation (well/moderate or poorly 
differentiated), and the presence or not of signet-ring 
cell morphology, lymphovascular permeation, perineu-
ral invasion, and Helicobacter pylori. CEA and CA19-9 
were measured using a chemiluminescent immunoassay 
sandwich method (Beckman Coulter, CA). A positive H. 
pylori test was defined as either the presence of H. pylori 
organisms in tissue immunohistochemically or a positive 
Campylobacter-like organism test.
Statistical analyses
The clinical characteristics of the groups (with or with-
out adjuvant chemotherapy) were compared using a Chi 
square test for categorical variables and a Student’s t test 
for continuous variables. Relapse-free survival was the 
time interval between the gastrectomy date and the date 
of disease relapse. Overall survival was calculated from 
the diagnosis to date of death from any cause or the last 
follow-up date. Both the relapse-free survival curve and 
the overall survival curve were created using the Kaplan–
Meier method. Statistical analysis was carried out using 
SPSS version 18 for Windows (IBM Corporation, Armonk, 
NY, USA) and SAS/JMP version 11 (SAS Institute Inc., 
Cary, NC, USA). Data are expressed as mean ± SD. All sta-
tistical tests were two-sided, and the differences were con-
sidered statistically significant at a P value <0.05.
Results
Patient baseline characteristics
Between January 2008 and December 2012, 194 patients 
were diagnosed as having stage II (n =  77) or stage III 
(n  =  117) GEJ or gastric adenocarcinoma after radical 
operation plus D2 lymph node dissection at China Medi-
cal University Hospital. There were 125 male (64.4  %) 
and 69 female patients (35.6 %). The median age was 67.7 
± 12.7 (range 33.9–97.5) years. Six (3.1 %) patients had 
performance status ECOG 3 and 28 (14.4 %) patients had 
cancer from GEJ. Five patients died of acute complication 
after surgery (1 acute renal failure, 1 acute myocardial 
infarction, 1 massive bleeding, 1 pneumonia and 1 mul-
tiple organ failure).
For patients with stage II gastric cancer, 37 received 
adjuvant chemotherapy (9 intravenous 5-fluorouracil, 17 
UFT, 11 S-1) while 40 did not. For stage III patients, 79 
received adjuvant chemotherapy (8 intravenous 5-fluo-
rouracil, 18 UFT, 4 capecitabine, 7 S-1, 23 intravenous 
5-fluorouracil plus a platinum, 3 capecitabine plus a 
platinum, 16 concurrent chemoradiotherapy with intra-
venous 5-fluorouracil) while 38 did not.
With a median follow-up duration of 23.3 ± 18.6 (range 
0.4–80.2) months, the median relapse-free survival was 
not reached (Fig.  1a), while the median overall survival 
time of the whole population was 42.6 months (Fig. 1b). 
For patients with stage II gastric cancer, both the median 
relapse-free survival and median overall survival time 
were not yet reached (Fig.  1c, d). For stage III patients, 
the median relapse-free survival and median overall sur-
vival time was 20.3  ±  2.6 (95  % CI 15.3–25.3) months 
(Fig.  1d) and 24.2  ±  2.4 (95  % CI 19.6–28.9) months 
(Fig.  1d), respectively. Stage was a significant prognos-
tic factor for either progression-free survival or overall 
survival.
Adjuvant chemotherapy prolongs relapse‑free and overall 
survival for patients with stage III gastric cancer
The influence of adjuvant chemotherapy on relapse-free 
survival and overall survival was first examined in all 
patients with stage II or stage III disease. Although adju-
vant chemotherapy did not benefit patients in terms of 
relapse-free survival (P = 0.887, Fig. 2a), it prolonged the 
overall survival time from 26.4 to 42.7 months (P = 0.039, 
Fig. 2b).
The significance of adjuvant chemotherapy was then 
evaluated for stage II (N =  77) and stage III (N =  117) 
patients separately. The adjuvant chemotherapy did not 
affect the relapse-free survival (P  =  0.936, Fig.  2c) or 
overall survival (P = 0.304, Fig. 2d) for stage II patients. 
To the contrary, adjuvant chemotherapy prolonged both 
the relapse-free survival and overall survival for patients 
with stage III gastric cancer. The median relapse-free sur-
vival time was 22.9 ± 6.9 (95 % CI 9.4–36.4) months and 
14.2 ± 2.9 (95 % CI 8.6–19.8) months for patients with or 
without adjuvant chemotherapy, respectively (P = 0.009, 
Fig. 2e). The median overall survival time was also pro-
longed in stage III patients to 32.3 ± 4.9 (95 % CI 22.6–
42.0) months with adjuvant chemotherapy compared to 
13.4 ± 2.0 (95 % CI 9.5–17.2) months without (P < 0.001, 
Fig. 2f ).
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Stage II patients with positive node may benefit 
from adjuvant chemotherapy in overall survival
Because resectable gastric cancer patients with lymph 
node involvement have been reported to benefit more 
from adjuvant chemotherapy compared with patients 
without node involvement (Noh et  al. 2014; Diaz-Nieto 
et  al. 2013), we then evaluated the impact of adjuvant 
chemotherapy on the survival of stage II patients with or 
without node involvement (Fig. 3). Adjuvant chemother-
apy did not affect the overall survival of patients without 
regional lymph node involvement (P  =  0.618, Fig.  3a). 
Although there appeared to be a trend in adjuvant chem-
otherapy prolonging the overall survival of patients with 
lymph node involvement, the difference between these 
two populations was also not statistically significant 
(P = 0.102, Fig. 3b).
Adjuvant chemotherapy prolongs relapse‑free and overall 
survival for patients aged <75 years with stage III gastric 
cancer
It is not surprising that elderly patients are less willing to 
accept chemotherapy than younger ones. To reduce the 
selection bias from age and take a closer look at the effect 
of adjuvant chemotherapy on survival, 142 patients aged 
<75 years were included in the survival analysis (Table 1). 
Ninety-eight patients received adjuvant chemotherapy 
while 44 did not. The baseline characteristic of patients 
in the two groups were similar except that patients in 
the adjuvant group had more lymph node involvement 
(P  =  0.040). As shown in Fig.  4, adjuvant chemother-
apy did not benefit the relapse-free survival (P =  0.981, 
Fig. 4a) or overall survival (P = 0.438, Fig. 4b) of stage II 
patients aged <75 years. For patients with stage III gastric 
Fig. 1 Kaplan–Meier curve of relapse‑free survival and overall survival. a, b All patients (n = 194). c, d The survival curves are stratified by stage
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cancer, adjuvant chemotherapy extended the median 
relapse-free survival from 11.2  ±  5.9 (95  % CI 0.0–
22.7) months to 22.6 ± 4.4 (95 % CI 14.0–31.3) months 
(P = 0.004, Fig. 4c), and the median overall survival from 
14.4 ± 2.5 (95 % CI 9.5–19.4) months to 32.3 ± 4.9 (95 % 
CI 22.7–41.9) months (P = 0.003, Fig. 4d).
Fig. 2 Kaplan–Meier curve of relapse‑free survival and overall survival according to adjuvant chemotherapy. a, b All patients (n = 194). c, d Patients 
with stage II gastric cancer (n = 77). e, f Patients with stage III gastric cancer (n = 117)
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Discussion
Our study is a real-world observation of the benefit of 
adjuvant chemotherapy for patients with stages II and 
III GEJ or gastric adenocarcinoma. The characteristic 
of patients were not the same as those in clinical trials. 
For example, the median age of patients in our study 
was 67.7  years which was higher than the median age 
of 63 years and 56 years in the S1 trial and in the CLAS-
SIC trial, respectively (Sakuramoto et al. 2007; Bang et al. 
2012). However, our analysis confirms the benefit of 
adjuvant chemotherapy in patients with stages II/III gas-
tric cancer outside a clinical trial. Furthermore, patients 
with stage III gastric cancer have a higher survival benefit 
from adjuvant chemotherapy than patients with stage II 
gastric cancer.
Although the value of adjuvant chemotherapy for gas-
tric cancer is getting general agreement by evidence pro-
vided by phase III trials, there are still debates on several 
issues. First, the optimal regimens of adjuvant chemo-
therapy for gastric cancer are not yet clearly defined. 
The efficacy of S-1 (Sakuramoto et al. 2007; Sasako et al. 
2011), UFT (Nakajima et  al. 2007), XELOX (Noh et  al. 
2014; Bang et al. 2012), or ECX (epirubicin, cisplatin and 
capecitabine) (Cunningham et  al. 2006) in adjuvant set-
tings have been successfully demonstrated in individual 
phase III clinical trials. It is also unknown if combina-
tion chemotherapy is more effective than a single agent. 
Second, the populations of patients and the inclusion 
criteria used in different studies were not the same. In 
the UFT trial, only patients with T2N1-2 were enrolled 
into the trial (Nakajima et al. 2007). However, in the TS-1 
trial, patients with stage II (excluding T1 cases), IIIA 
or IIIB were eligible for adjuvant therapy (Sakuramoto 
et al. 2007). In the CLASSIC trial, patients were eligible 
if they had stage II (T2N1, T1N2, T3N0), IIIA (T3N1, 
T2N2, T4N0) or IIIB (T3N2) gastric cancer (AJCC 6th) 
(Greene et al. 2002). Third, the individual values of adju-
vant chemotherapy for stage II or stage III were not the 
primary endpoints and thus were less addressed in the 
trials at the beginning. Although there were subgroup 
analyses, the benefits of adjuvant chemotherapy for stage 
II or stage III are not universal in trials. In the subgroup 
analysis of the S-1 adjuvant study, patients with stages 
II and IIIA disease had a 5-year relapse-free survival 
and 5-year overall survival benefit from adjuvant S-1 in 
contrast with patients with stage IIIB disease (Sasako 
et al. 2011). In the follow-up report of the CLASSIC trial 
(adjuvant XELOX), either patients with stage II, stage 
IIIA or stage IIIB gastric cancer had a 5-year disease-
free survival benefit from adjuvant XELOX. However, 
only patients with stage II gastric cancer benefited from 
adjuvant XELOX for a 5-year overall survival rate (Noh 
et  al. 2014). Because of the high relapse rate for stage 
III gastric cancer and the insignificant benefit of S-1 for 
patients with stage IIIB disease in the subgroup analysis 
of adjuvant S-1 study (Sasako et al. 2011), the regimen of 
adjuvant chemotherapy at our institute was a fluorouracil 
derivative and a combination of a platinum and a fluoro-
uracil derivative for patients with stages II and III gastric 
cancer, respectively.
The survival benefit of adjuvant therapy for patients 
with stage II only gastric cancer is rarely addressed (Chen 
et al. 2011). Although the subgroup analysis in either the 
TS-1 or CLASSIC trial suggested a positive effect of adju-
vant chemotherapy for patients with stage II disease, con-
troversial results have been reported (Chen et  al. 2011; 
Fig. 3 Kaplan–Meier overall survival curve of patients with stage II gastric cancer according to adjuvant chemotherapy. a Patients without lymph 
node involvement. b Patients with lymph node involvement
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Coburn et al. 2008). Chen and colleagues retrospectively 
analyzed 268 patients with stage II gastric cancer who 
received adjuvant chemotherapy with either FAM regi-
men (5-fluorouracil, doxorubicin and mitomycin-C) or 
FOLFOX regimen (oxaliplatin, leucovorin and 5-fluoro-
uracil) after D2 resection (Chen et  al. 2011). The 1-, 3-, 
5-, and 10-year overall survival rate was similar between 
patients who received adjuvant chemotherapy and those 
who did not. This uncertainty of adjuvant therapy for 
patients with stage II gastric cancer is also reflected by 
a retrospective analysis of the surveillance epidemi-
ology and end results (SEER) database (Coburn et  al. 
2008). In this population-based analysis, adjuvant radio-
therapy improved the overall survival of patients with 
stages III and IV M0 gastric cancer, but not for patients 
with stage IB and II gastric cancer (Coburn et al. 2008). 
In our study, the adjuvant chemotherapy did not ben-
efit patients with stage II gastric cancer as well as those 
with stage III. There are a couple possible explanations. 
First, the adjuvant chemotherapeutic regimens for stage 
II gastric cancer used at our institute, which include UFT 
and intravenous 5-fluorouracil infusion without a plati-
num, are less potent than the XELOX agents used in the 
CLASSIC trial. Second, only 77 patients with stage II gas-
tric cancer are included in our analysis.
Although the overall survival benefit of adjuvant chem-
otherapy was not realized for stage II patients, we found 
an apparent trend of the benefit for patients who had 
metastatic disease in lymph nodes (P = 0.102) compared 
with those who were node negative. The observation that 
patients with positive lymph node had more benefit from 
adjuvant chemotherapy has also been noted in the CLAS-
SIC trial (Noh et al. 2014) and in the meta-analysis of the 
Cochrane Database (Diaz-Nieto et al. 2013). In the sub-
group analysis of the CLASSIC trial, the adjuvant XELOX 
did not improve the overall survival for patients without 
node involvement (hazard ratio 0.79, 95 % CI 0.32–1.95), 
but did benefit for patients with lymph node involve-
ment (hazard ratio 0.67, 95  % CI 0.51–0.87) (Noh et  al. 
2014). Similarly, the value of adjuvant chemotherapy on 
overall survival was demonstrated by a meta-analysis for 
patients with node involvement (hazard ratio 0.78, 95 % 
CI 0.67–0.91), but did not benefit patients without lymph 
node involvement (hazard ratio 0.74, 95 % CI 0.41–1.33) 
(Diaz-Nieto et al. 2013).
There are several caveats in our study that deserve 
further attention. First, this was a retrospective study 
conducted in a single institute. Second, the regimens of 
adjuvant chemotherapy used in our institute in the time 
period examined have now been replaced by newer or 
more intensive regimens in other countries. Since the 
reports of phase III trials, the use of adjuvant S-1 and 
XELOX has increased in recent years. However, both 
regimens are currently not reimbursed by the National 
Health Insurance in Taiwan. Therefore, chemotherapy 
with UFT, intravenous infusion of 5-fluorouracil with or 
without cisplatin, although less updated, is still widely 
used in adjuvant condition in Taiwan. Accordingly, our 
study reflects a real-world condition in which medi-
cal insurance determines the use of medication in most 
Table 1 Baseline characteristics of  stages II/III gastric 
cancer patients aged <75  years with  or without  adjuvant 
chemotherapy
CEA carcinoembryonic antigen, GEJ gastroesophageal junction, HP Helicobacter 
pylori, F female, LN lymph node, M male, PS performance status, SD standard 
deviation
Chi square test; a Student’s t test
Adjuvant chemotherapy P value
With n (%) Without n (%)
Number of patients 98 44
Age (year), median ± SDa 60.0 ± 9.3 64.7 ± 10.8 0.141
Gender, M/F 60/38 29/15 0.708
Smoking 38 (38.8) 17 (38.6) 1.000
Alcohol drinking 30 (30.6) 14 (31.8) 1.000
History of gastric operation 2 (2.0) 4 (9.1) 0.074
Location 0.371
 GEJ 11 (11.2) 6 (13.6)
 Stomach 87 (88.8) 38 (86.4)
PS
 0, 1 93 (94.9) 40 (90.9) 0.459
 2, 3 5 (5.1) 4 (9.1)
Preoperative CEA (ng/ml), 
median ± SDa
1.9 ± 6.8 2.3 ± 25.2 0.063
Preoperative CA19‑9 (U/ml), 
median ± SDa
10.8 ± 88.7 7.4 ± 964.0 0.331
Tumor size 0.701
 T1 4 (4.1) 0 (0.0)
 T2 8 (8.2) 4 (9.1)
 T3 49 (50.0) 26 (59.1)
 T4 37 (37.7) 14 (31.8)
LN involvement
 N0 13 (13.3) 11 (25.0) 0.040
 N1 10 (10.2) 9 (20.5)
 N2 34 (34.7) 6 (13.6)
 N3 41 (41.8) 18 (40.9)
Differentiation 0.820
 Well/moderate 20 (20.4) 9 (20.5)
 Poor 78 (79.6) 35 (79.5)
Signet ring cell 43 (47.3) 21 (47.7) 0.705
Lymphovascular permeation 83 (84.7) 33 (75.0) 0.312
Perineural invasion 83 (84.7) 30 (68.2) 0.053
HP 0.467
 Positive 41/72 (56.9) 10/21 (47.6)
 Negative 31/72 (43.1) 11/21 (52.4)
Page 8 of 9Chiu et al. SpringerPlus  (2016) 5:728 
situations. Third, there were several kind of regimens 
used for adjuvant indication at our institute (see “Patient 
baseline characteristics” section). This heterogeneity 
of adjuvant regimen renders the analysis of influence of 
individual regimen on survival time impossible.
Conclusions
In summary, our study provides evidence that adju-
vant chemotherapy confer a relapse-free survival and an 
overall survival benefit for patients with stage III gastric 
cancer in a real-world situation. An apparent trend for 
an overall survival benefit also exists for stage II patients 
with positive lymph nodes. Tailoring therapy depending 
on different characteristics for patients with stage II gas-
tric cancer may therefore produce better outcomes; how-
ever, further prospective trials are needed.
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